

Antoine Italiano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6482312/publications.pdf>

Version: 2024-02-01

211
papers

16,400
citations

23879

60
h-index

21239

119
g-index

214
all docs

214
docs citations

214
times ranked

20304
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>CINSARC</sc> in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <sc>ISG–STS</sc> 1001 study. Cancer Medicine, 2023, 12, 1350-1357.	1.3	7
2	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 417-431.	2.0	6
3	Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. International Journal of Cancer, 2022, 150, 645-653.	2.3	9
4	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase <sc>I</sc>/<sc>II</sc> open-label, dose escalation study. International Journal of Cancer, 2022, 150, 993-1006.	2.3	28
5	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. Journal of Clinical Oncology, 2022, 40, 752-761.	0.8	189
6	Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. European Journal of Cancer, 2022, 162, 161-169.	1.3	22
7	Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox. European Journal of Cancer, 2022, 162, 128-129.	1.3	2
8	Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial. ESMO Open, 2022, 7, 100340.	2.0	9
9	Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. , 2022, 10, e003697.		28
10	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
11	Gene expression profiling improves prognostication by nomogram in patients with soft-tissue sarcomas. Cancer Communications, 2022, 42, 563-566.	3.7	4
12	Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. Clinical Cancer Research, 2022, 28, 1087-1097.	3.2	22
13	Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG). ESMO Open, 2022, 7, 100402.	2.0	8
14	Prognostic Significance of Bone Metastasis in Soft Tissue Sarcoma Patients Receiving Palliative Systemic Therapy: An Explorative, Retrospective Pooled Analysis of the EORTC-Soft Tissue and Bone Sarcoma Group (STBSG) Database. Sarcoma, 2022, 2022, 1-13.	0.7	1
15	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2022, 40, 2479-2490.	0.8	15
16	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176
17	Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study. Clinical Cancer Research, 2022, 28, 1765-1772.	3.2	17
18	Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. Gynecologic Oncology, 2022, 166, 211-218.	0.6	20

#	ARTICLE	IF	CITATIONS
19	Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. , 2022, 10, e003890.		37
20	Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. Cancer Immunology, Immunotherapy, 2022, 71, 2985-2998.	2.0	5
21	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nature Medicine, 2022, 28, 1199-1206.	15.2	88
22	Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer. Annals of Oncology, 2022, 33, 1084-1085.	0.6	10
23	Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Annals of Oncology, 2022, 33, 1041-1051.	0.6	22
24	Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. Gynecologic Oncology, 2022, 166, 245-253.	0.6	3
25	Model Informed Dosing Regimen and Phase I Results of the Anti-IL-1 Antibody Budigalimab (ABBV-181). Clinical and Translational Science, 2021, 14, 277-287.	1.5	5
26	Incidence and prognostic factors of clinically meaningful toxicities of kinase inhibitors in older patients with cancer: The PreToxE study. Journal of Geriatric Oncology, 2021, 12, 668-671.	0.5	1
27	New insights into the clinical management of advanced gastrointestinal stromal tumors. Expert Opinion on Pharmacotherapy, 2021, 22, 439-447.	0.9	0
28	The safety of current pharmacotherapeutic strategies for osteosarcoma. Expert Opinion on Drug Safety, 2021, 20, 427-438.	1.0	11
29	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. Bulletin Du Cancer, 2021, 108, 163-176.	0.6	7
30	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. Cancer Medicine, 2021, 10, 2645-2659.	1.3	23
31	Targeting the VEGF Pathway in Osteosarcoma. Cells, 2021, 10, 1240.	1.8	24
32	Determinants of the access to remote specialised services provided by national sarcoma reference centres. BMC Cancer, 2021, 21, 631.	1.1	14
33	Impact of Disease Evolution on Efficacy Outcomes From Larotrectinib in Patients With Locally Advanced or Metastatic TROPOMYOSIN RECEPTOR KINASE FUSION-POSITIVE SOLID TUMORS. JCO Precision Oncology, 2021, 5, 1458-1465.	1.5	4
34	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer, 2021, 2, 794-802.	5.7	173
35	Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Annals of Oncology, 2021, 32, 1381-1390.	0.6	33
36	Implementing a Machine Learning Strategy to Predict Pathologic Response in Patients With Soft Tissue Sarcomas Treated With Neoadjuvant Chemotherapy. JCO Clinical Cancer Informatics, 2021, 5, 958-972.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients. <i>Annals of Oncology</i> , 2021, 32, 1642-1645.	0.6	7
38	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405.	0.7	6
39	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. <i>BMC Cancer</i> , 2021, 21, 1180.	1.1	9
40	GSK3-beta as a candidate therapeutic target in soft tissue sarcomas. <i>Journal of Hematology and Oncology</i> , 2021, 14, 202.	6.9	3
41	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. <i>Frontiers in Immunology</i> , 2021, 12, 775761.	2.2	45
42	Results of APIâ€‘AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcomeâ€‘09 study. <i>International Journal of Cancer</i> , 2020, 146, 413-423.	2.3	18
43	A new standard of care for patients with high-risk rhabdomyosarcoma?. <i>Lancet Oncology, The</i> , 2020, 21, e2.	5.1	0
44	Systematic review of sarcomas radiomics studies: Bridging the gap between concepts and clinical applications?. <i>European Journal of Radiology</i> , 2020, 132, 109283.	1.2	35
45	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapyâ€‘A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020, 215, 1539-1548.	1.0	21
46	Impact of CT-based body composition parameters at baseline, their early changes and response in metastatic cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Radiology</i> , 2020, 133, 109340.	1.2	15
47	Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. <i>Lancet Oncology, The</i> , 2020, 21, 1423-1432.	5.1	194
48	High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. <i>EBioMedicine</i> , 2020, 62, 103131.	2.7	32
49	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. <i>European Journal of Cancer</i> , 2020, 141, 162-170.	1.3	29
50	MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. <i>Cancers</i> , 2020, 12, 2253.	1.7	10
51	Onapristone Extended Release: Safety Evaluation from Phase Iâ€‘II Studies with an Emphasis on Hepatotoxicity. <i>Drug Safety</i> , 2020, 43, 1045-1055.	1.4	10
52	Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting. <i>Cancers</i> , 2020, 12, 3058.	1.7	9
53	Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. <i>Oncolmmunology</i> , 2020, 9, 1792036.	2.1	31
54	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. <i>Lancet Oncology, The</i> , 2020, 21, 1353-1365.	5.1	1,363

#	ARTICLE	IF	CITATIONS
55	Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. <i>ESMO Open</i> , 2020, 5, e001081.	2.0	6
56	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198.	2.3	288
57	PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. <i>Journal of Hematology and Oncology</i> , 2020, 13, 55.	6.9	47
58	ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status. <i>Scientific Reports</i> , 2020, 10, 7488.	1.6	16
59	Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. <i>Annals of Oncology</i> , 2020, 31, 822-823.	0.6	24
60	IDO Targeting in Sarcoma: Biological and Clinical Implications. <i>Frontiers in Immunology</i> , 2020, 11, 274.	2.2	24
61	LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. <i>Cancers</i> , 2020, 12, 757.	1.7	18
62	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2020, 21, 446-455.	5.1	182
63	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	13.7	1,158
64	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , 2020, 126, 45-55.	1.3	9
65	High-Grade Soft-Tissue Sarcomas: Can Optimizing Dynamic Contrast-Enhanced MRI Postprocessing Improve Prognostic Radiomics Models?. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 282-297.	1.9	21
66	Targeting epigenetics in sarcomas through EZH2 inhibition. <i>Journal of Hematology and Oncology</i> , 2020, 13, 33.	6.9	27
67	High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response. <i>European Radiology</i> , 2019, 29, 545-555.	2.3	13
68	Local and Metastatic Relapse Features in Patients After a Primary Soft Tissue Sarcoma: Advocating for a Better-Tailored Follow-Up. <i>Frontiers in Oncology</i> , 2019, 9, 559.	1.3	2
69	Pazopanib or methotrexate+vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2019, 20, 1263-1272.	5.1	123
70	Olaratumab failure in sarcomas: what are the lessons learned?. <i>European Journal of Cancer</i> , 2019, 117, 69-70.	1.3	5
71	Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma. <i>Annals of Oncology</i> , 2019, 30, v523-v524.	0.6	2
72	Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, v715-v716.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019, 9, 14551.	1.6	41
74	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019, 119, 151-157.	1.3	103
75	Pazopanib for progressive desmoid tumours: children, persistant effects, and cost – Author's reply. <i>Lancet Oncology</i> , The, 2019, 20, e556.	5.1	0
76	Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition. <i>Journal of Hematology and Oncology</i> , 2019, 12, 11.	6.9	11
77	Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-EPD-1. <i>Breast Journal</i> , 2019, 25, 971-973.	0.4	8
78	Abnormal vascularization of soft-tissue sarcomas on conventional MRI: Diagnostic and prognostic values. <i>European Journal of Radiology</i> , 2019, 117, 112-119.	1.2	6
79	Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. <i>Annals of Oncology</i> , 2019, 30, 1381-1392.	0.6	120
80	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	3.2	181
81	Surgery in reference centers improves survival of sarcoma patients: a nationwide study. <i>Annals of Oncology</i> , 2019, 30, 1143-1153.	0.6	191
82	Influence of temporal parameters of DCE-MRI on the quantification of heterogeneity in tumor vascularization. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1773-1788.	1.9	19
83	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. <i>Clinical Cancer Research</i> , 2019, 25, 4611-4615.	3.2	13
84	Sarcomas in patients over 90: Natural history and treatment – A nationwide study over 6 years. <i>International Journal of Cancer</i> , 2019, 145, 2135-2143.	2.3	10
85	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1470-1478.	0.8	671
86	Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. <i>American Journal of Surgical Pathology</i> , 2019, 43, 268-276.	2.1	96
87	Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 35-42.	2.0	16
88	Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis. <i>Oncologist</i> , 2019, 24, e559-e564.	1.9	5
89	Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition. <i>Journal of Hematology and Oncology</i> , 2019, 12, 116.	6.9	0
90	Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma. <i>Frontiers in Oncology</i> , 2019, 9, 1204.	1.3	30

#	ARTICLE	IF	CITATIONS
91	T ₂ -based MRI Delta-radiomics improve response prediction in soft-tissue sarcomas treated by neoadjuvant chemotherapy.. Journal of Magnetic Resonance Imaging, 2019, 50, 497-510.	1.9	74
92	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncology, The, 2019, 20, 120-133.	5.1	222
93	Patterns of Care and Outcome Radiation-Induced Soft Tissue Sarcomas. International Journal of Radiation Oncology Biology Physics, 2019, 103, 449-452.	0.4	7
94	Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).. Journal of Clinical Oncology, 2019, 37, 11003-11003.	0.8	50
95	Newer therapeutic strategies for soft-tissue sarcomas. , 2018, 188, 118-123.		5
96	Prospective assessment of the predictive value of the <i>BRCA1</i> gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. Cancer Medicine, 2018, 7, 1575-1577.	1.3	6
97	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncology, The, 2018, 19, 649-659.	5.1	450
98	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. Oncologist, 2018, 23, 1250-1259.	1.9	25
99	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). International Journal of Cancer, 2018, 142, 2610-2620.	2.3	32
100	CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. Annals of Oncology, 2018, 29, 1023-1029.	0.6	13
101	Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. Critical Reviews in Oncology/Hematology, 2018, 123, 21-41.	2.0	33
102	PD-1 inhibition in sarcoma still needs investigation. Lancet Oncology, The, 2018, 19, e6.	5.1	14
103	Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas. JAMA Oncology, 2018, 4, 1398.	3.4	78
104	Role of perioperative chemotherapy in soft-tissue sarcomas: It's time to end a never-ending story. European Journal of Cancer, 2018, 97, 53-54.	1.3	6
105	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2018, 19, 639-648.	5.1	81
106	Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. Annals of Oncology, 2018, 29, 1304-1311.	0.6	51
107	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. JAMA Oncology, 2018, 4, 93.	3.4	303
108	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55

#	ARTICLE	IF	CITATIONS
109	The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. <i>Annals of Oncology</i> , 2018, 29, 459-465.	0.6	24
110	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. <i>Oncoimmunology</i> , 2018, 7, e1386828.	2.1	36
111	Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. <i>European Journal of Cancer</i> , 2018, 88, 57-66.	1.3	74
112	Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891. <i>Annals of Oncology</i> , 2018, 29, viii144.	0.6	3
113	A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950). <i>Annals of Oncology</i> , 2018, 29, viii580-viii581.	0.6	12
114	Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. <i>Journal of Clinical Oncology</i> , 2018, 36, 160-167.	0.8	94
115	Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. <i>Cancers</i> , 2018, 10, 417.	1.7	36
116	Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). <i>Annals of Oncology</i> , 2018, 29, viii670.	0.6	6
117	Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?. <i>Current Treatment Options in Oncology</i> , 2018, 19, 78.	1.3	11
118	Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. <i>PLoS ONE</i> , 2018, 13, e0204973.	1.1	18
119	Molecular determinants of acquired resistance to BRAF inhibition in human lung cancer. <i>Lung Cancer</i> , 2018, 126, 227-229.	0.9	3
120	Trends in Modern Phase 1 Oncology Trials. <i>New England Journal of Medicine</i> , 2018, 379, 1188-1189.	13.9	3
121	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , 2018, 7, 4023-4035.	1.3	39
122	Targeting ERBB2 mutations in solid tumors: biological and clinical implications. <i>Journal of Hematology and Oncology</i> , 2018, 11, 86.	6.9	28
123	Encouraging Trends in Modern Phase 1 Oncology Trials. <i>New England Journal of Medicine</i> , 2018, 378, 2242-2243.	13.9	58
124	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018, 99, 28-36.	1.3	13
125	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 34617-34627.	0.8	9
126	Clinical impact of extensive molecular profiling in advanced cancer patients. <i>Journal of Hematology and Oncology</i> , 2017, 10, 45.	6.9	17

#	ARTICLE	IF	CITATIONS
127	Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma. Expert Opinion on Pharmacotherapy, 2017, 18, 819-824.	0.9	8
128	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Medicine, 2017, 15, 78.	2.3	143
129	Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours. European Journal of Cancer, 2017, 81, 102-105.	1.3	3
130	Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment. Annals of Oncology, 2017, 28, 3108.	0.6	17
131	High-depth sequencing of paired primary and metastatic tumours: Implications for personalised medicine. European Journal of Cancer, 2017, 84, 250-256.	1.3	7
132	Clinical activity of eribulin in advanced desmoplastic small round-cell tumor. Anti-Cancer Drugs, 2017, 28, 1053-1055.	0.7	9
133	CSF-1R Inhibitor Development: Current Clinical Status. Current Oncology Reports, 2017, 19, 70.	1.8	78
134	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. European Journal of Cancer, 2017, 83, 125-131.	1.3	134
135	Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. European Journal of Cancer, 2017, 83, 194-202.	1.3	14
136	<i>NUT</i> carcinoma in children and adults: A multicenter retrospective study. Pediatric Blood and Cancer, 2017, 64, e26693.	0.8	65
137	Olaratumab for soft tissue sarcoma. Expert Opinion on Biological Therapy, 2017, 17, 1019-1025.	1.4	4
138	Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. Journal of Hematology and Oncology, 2017, 10, 84.	6.9	23
139	Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. Journal of Hematology and Oncology, 2017, 10, 123.	6.9	81
140	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. British Journal of Cancer, 2017, 117, 1787-1797.	2.9	30
141	Improved overall and progression free survival after surgery in expert sites for sarcoma patients: A nationwide study of FSG-GETO/NETSARC. Annals of Oncology, 2017, 28, v521.	0.6	5
142	Improved survival using specialized multidisciplinary board in sarcoma patients. Annals of Oncology, 2017, 28, 2852-2859.	0.6	255
143	Genetic landscape of soft-tissue sarcomas: Moving toward personalized medicine.. Journal of Clinical Oncology, 2017, 35, 11002-11002.	0.8	9
144	Clinical, radiological and genetic features, associated with the histopathologic response to neoadjuvant chemotherapy (NAC) and outcomes in locally advanced soft tissue sarcoma (STS) patients (pts).. Journal of Clinical Oncology, 2017, 35, 11014-11014.	0.8	10

#	ARTICLE	IF	CITATIONS
145	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).. Journal of Clinical Oncology, 2017, 35, 11058-11058.	0.8	21
146	Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications. Oncotarget, 2017, 8, 7878-7890.	0.8	17
147	Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. , 2016, 165, 26-31.		42
148	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. European Journal of Cancer, 2016, 58, 90-96.	1.3	111
149	Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Annals of Oncology, 2016, 27, 1178-1179.	0.6	71
150	Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point. Annals of Oncology, 2016, 27, 1974-1975.	0.6	4
151	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. Journal of Clinical Oncology, 2016, 34, 3898-3905.	0.8	151
152	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clinical Cancer Research, 2016, 22, 4550-4555.	3.2	73
153	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 1732-1742.	5.1	200
154	PRognostic factor of Early Death In phase II Trials or the end of "sufficient life expectancy"™ as an inclusion criterion? (PREDIT model). BMC Cancer, 2016, 16, 768.	1.1	3
155	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 1070-1080.	5.1	170
156	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2016, 387, 1629-1637.	6.3	610
157	Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. Lancet Oncology, The, 2016, 17, 532-538.	5.1	134
158	A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy. Annals of Oncology, 2016, 27, 199-200.	0.6	12
159	Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity.. Journal of Clinical Oncology, 2016, 34, 11008-11008.	0.8	11
160	PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53. BMC Cancer, 2015, 15, 684.	1.1	27
161	Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin. PLoS ONE, 2015, 10, e0137794.	1.1	12
162	CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncology, The, 2015, 16, 949-956.	5.1	298

#	ARTICLE	IF	CITATIONS
163	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 531-540.	5.1	56
164	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2797-2802.	0.8	153
165	BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients. <i>British Journal of Cancer</i> , 2015, 112, 688-692.	2.9	18
166	Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study. <i>Annals of Oncology</i> , 2015, 26, 1465-1470.	0.6	15
167	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan- α -Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3401-3408.	0.8	324
168	VEGFA targeting in capillary hemangiomas. <i>Journal of Neuro-Oncology</i> , 2015, 125, 443-444.	1.4	4
169	Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10547-10547.	0.8	1
170	Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3005-3005.	0.8	28
171	Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. <i>Cancer</i> , 2014, 120, 3361-3369.	2.0	68
172	Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study. <i>Annals of Oncology</i> , 2014, 25, 225-231.	0.6	39
173	Long-term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow-up. <i>Cancer</i> , 2014, 120, 3003-3006.	2.0	40
174	Quality of reporting of phase II trials: a focus on highly ranked oncology journals. <i>Annals of Oncology</i> , 2014, 25, 536-541.	0.6	16
175	Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 730-734.	0.6	91
176	Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 735-742.	0.6	149
177	Consistent <i>SMARCB1</i> homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 475-486.	1.5	120
178	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	7.7	1,033
179	Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2535-2535.	0.8	36
180	Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. <i>Targeted Oncology</i> , 2013, 8, 211-213.	1.7	47

#	ARTICLE	IF	CITATIONS
181	Sorafenib in patients with progressive epithelioid hemangioendothelioma. <i>Cancer</i> , 2013, 119, 2639-2644.	2.0	97
182	Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. <i>Targeted Oncology</i> , 2013, 8, 295-300.	1.7	13
183	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. <i>Annals of Oncology</i> , 2013, 24, 2681-2685.	0.6	19
184	Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. <i>Annals of Oncology</i> , 2013, 24, 1924-1930.	0.6	43
185	Chromosome Instability Accounts for Reverse Metastatic Outcomes of Pediatric and Adult Synovial Sarcomas. <i>Journal of Clinical Oncology</i> , 2013, 31, 608-615.	0.8	135
186	Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics. <i>Clinical Cancer Research</i> , 2013, 19, 1190-1196.	3.2	46
187	Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10514-10514.	0.8	17
188	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10516-10516.	0.8	8
189	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2012, 23, 1601-1607.	0.6	117
190	Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). <i>Annals of Oncology</i> , 2012, 23, 182-186.	0.6	130
191	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncology</i> , The, 2012, 13, 1133-1140.	5.1	490
192	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012, 118, 3330-3336.	2.0	118
193	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. <i>Annals of Surgical Oncology</i> , 2012, 19, 1551-1559.	0.7	57
194	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	2.0	222
195	Temsirolimus in advanced leiomyosarcomas. <i>Anti-Cancer Drugs</i> , 2011, 22, 463-467.	0.7	26
196	Trends in survival for patients with metastatic soft tissue sarcoma. <i>Cancer</i> , 2011, 117, 1049-1054.	2.0	237
197	<i>ERCC5</i> , <i>XPG</i> , <i>ERCC1</i> and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. <i>Cancer</i> , 2011, 117, 3445-3456.	2.0	57
198	Quality of Randomized Controlled Trials Reporting in the Treatment of Sarcomas. <i>Journal of Clinical Oncology</i> , 2011, 29, 1204-1209.	0.8	43

#	ARTICLE	IF	CITATIONS
199	Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.. Journal of Clinical Oncology, 2011, 29, 10079-10079.	0.8	11
200	KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications. Annals of Surgical Oncology, 2010, 17, 1429-1434.	0.7	102
201	<i>KRAS</i> mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer, 2010, 116, 2682-2687.	2.0	67
202	Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Annals of Oncology, 2010, 21, 1135-1137.	0.6	108
203	Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Annals of Oncology, 2010, 21, 2436-2441.	0.6	112
204	Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Annals of Oncology, 2009, 20, 425-430.	0.6	129
205	Clinical and Biological Significance of <i>CDK4</i> Amplification in Well-Differentiated and Dedifferentiated Liposarcomas. Clinical Cancer Research, 2009, 15, 5696-5703.	3.2	124
206	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for anti-EGFR treatment of a rare lung malignancy. International Journal of Cancer, 2009, 125, 2479-2482.	2.3	103
207	Variability of origin for the neocentromeric sequences in anaphoid supernumerary marker chromosomes of well-differentiated liposarcomas. Cancer Letters, 2009, 273, 323-330.	3.2	21
208	<i>HMGA2</i> is the partner of <i>MDM2</i> in well-differentiated and dedifferentiated liposarcomas whereas <i>CDK4</i> belongs to a distinct inconsistent amplicon. International Journal of Cancer, 2008, 122, 2233-2241.	2.3	179
209	<i>NFIB</i> rearrangement in superficial, retroperitoneal, and colonic lipomas with aberrations involving chromosome band 9p22. Genes Chromosomes and Cancer, 2008, 47, 971-977.	1.5	37
210	Monosomy 7 and absence of 12q amplification in two cases of spindle cell liposarcomas. Cancer Genetics and Cytogenetics, 2008, 184, 99-104.	1.0	27
211	Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: The missing link between lipomas and liposarcomas?. International Journal of Cancer, 2007, 121, 308-315.	2.3	49